₹411.15
+₹4.75 (+1.17%)
Closed · As of 26 Aug 3:30 pm
Mkt Cap
₹16,591 Cr
P/E
75.14
ROE
7.76%
ROCE
9.67%
About Syngene International Ltd
Syngene International is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Syngene’s services include integrated drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process R&D, cGMP manufacturing, formulation and analytical development along with Clinical development services.
Founded
1993
CEO
Kiran Mazumdar Shaw
Employees
8,373
HQ
Bengaluru, Karnataka
About Syngene International Ltd
Syngene International is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Syngene’s services include integrated drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process R&D, cGMP manufacturing, formulation and analytical development along with Clinical development services.
Founded:1993
CEO:Kiran Mazumdar Shaw
Employees:8,373
HQ:Bengaluru, Karnataka
Finished Products
1Contract Research Fees
₹15,144.50Cr2Other Operating Revenue
₹650.60CrRaw Materials
1Chemicals and Reagents
₹4,204.50CrPrice Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹679
52W Low
₹375
Volume567.95K
Avg VolumeN/A
Beta0.87
Dividend Yield0.30%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
75.14x
Valuation
P/B Ratio
3.43x
Valuation
EPS
₹5.47
Valuation
Dividend Yield
0.30%
Valuation
ROE
7.76%
Profitability
ROCE
9.67%
Profitability
Revenue by Segment
Contribution & growth by business line
Providing contract research and manRevenue split N/A
Geographical Revenue Split
Domestic vs international exposure
Domestic
2.6%
International
97.4%
United States of America62.8%
Europe30.7%
Rest of the World3.9%
India2.6%
Strategic Relations
Collaborations, joint ventures & subsidiaries
No collaborations data available.
Forensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.09x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
2.3%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.